120
Participants
Start Date
December 7, 2023
Primary Completion Date
January 8, 2024
Study Completion Date
April 8, 2024
RSV/Flu-01E
Participants will receive single intranasal injection of RSV/Flu-01E vaccine in 0.5 ml, containing 8.4 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the F antigen of respiratory syncytial virus
Placebo
Participants will receive single intranasal injection of physiological buffer solution in 0.5 ml
Pavlov First Saint Petersburg State Medical University, Saint Petersburg
Smorodintsev Research Institute of Influenza, Saint Petersburg
St. Petersburg City Polyclinic No. 34, Saint Petersburg
Pavlov First Saint Petersburg State Medical University
OTHER
St. Petersburg City Polyclinic No. 34
UNKNOWN
Research Institute of Influenza, Russia
OTHER